FDA Looks To Strengthen, Speed Drug Reviews With Flow Of Quality Data

New Approach Would Overcome Legacy Burden Of ‘Electronic Paper’

 
• By Bowman Cox
FDA Chemist Collage
Progress from paper, to e-paper, to data

More from Manufacturing Focus

More from In Vivo